SCHEMBL1908379

SCHEMBL1908379

CCc1cccnc1Nc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 4/20 0.56
MEN1 O00255 7/20 0.51
KMT2A Q03164 7/20 0.51
MAPT P10636 4/20 0.51
ALDH1A1 P00352 3/20 0.51
GAA P10253 1/20 0.51
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
HPGD P15428 1/20 0.48
CYP2C19 P33261 1/20 0.48
GRM4 Q14833 1/20 0.45
RAB9A P51151 6/20 0.45
NPSR1 Q6W5P4 2/20 0.45
MAPK1 P28482 1/20 0.45
GRM5 P41594 2/20 0.44
NPC1 O15118 4/20 0.44
HTT P42858 2/20 0.44
ATM Q13315 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14604182 0.82 DHODH (0.56) DHODHMEN1KMT2AMAPTALDH1A1
SCHEMBL18951516 0.82 MEN1 (0.52) DHODHMEN1KMT2AMAPTALDH1A1
SCHEMBL1375014 0.82 DHODH (0.56) DHODHMEN1KMT2AMAPTALDH1A1
SCHEMBL9470451 0.82 DHODH (0.51) DHODHMEN1KMT2AMAPTALDH1A1
SCHEMBL5252795 0.82 DHODH (0.51) DHODHMEN1KMT2AMAPTALDH1A1
SCHEMBL3633702 0.81 DHODH (0.51) DHODHMEN1KMT2AMAPTALDH1A1
SCHEMBL13670336 0.80 DHODH (0.54) DHODHMEN1KMT2AMAPTALDH1A1
SCHEMBL9753940 0.78 BRD4 (0.48) DHODHMEN1KMT2AMAPTALDH1A1
SCHEMBL27975923 0.78 DHODH (0.47) DHODHMEN1KMT2AMAPTALDH1A1
SCHEMBL13653031 0.78 LMNA (0.63) DHODHMEN1KMT2AALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1649857-A2 New use of glutamate antagonists for the treatment of cancer Ikonomidou, Hrissanthi (DE) 2006-04-26 EP claimed
US-20050054650-A1 Use of glutamate antagonists for the treatment of cancer IKONOMIDOU HRISSANTHI (DE) 2005-03-10 US claimed
EP-1124553-A1 NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER Ikonomidou, Hrissanthi (DE) 2001-08-22 EP claimed
EP-1002535-A1 New use of glutamate antagonists for the treatment of cancer Ikonomidou, Hrissanthi (DE) 2000-05-24 EP claimed
WO-2000024395-A1 NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER IKONOMIDOU HRISSANTHI (DE) 2000-05-04 WO claimed
US-20130281523-A1 LOW DOSE CANNABINOID MEDICAMENTS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2013-10-24 US disclosed
US-20120231083-A1 SUSTAINED RELEASE CANNABINOID MEDICAMENTS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2012-09-13 US disclosed
US-8178496-B2 Photoreactive regulator of glutamate receptor function and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-05-15 US disclosed
WO-2011063164-A2 SUSTAINED RELEASE CANNABINOID MEDICAMENTS STEADY SLEEP RX CO., INC. (US) 2011-05-26 WO disclosed
US-20090181454-A1 PHOTOREACTIVE REGULATOR OF GLUTAMATE RECEPTOR FUNCTION AND METHODS OF USE THEREOF ENERGY, UNITED STATE DEPARTMENT OF 2009-07-16 US disclosed
US-7250394-B2 Treatment of glial tumors with glutamate antagonists NEDERGAARD MAIKEN 2007-07-31 US disclosed
US-7247610-B2 Use of glutamate antagonists for the treatment of cancer IKONOMIDOU HRISSANTHI 2007-07-24 US disclosed
US-20050054650-A1 Use of glutamate antagonists for the treatment of cancer IKONOMIDOU HRISSANTHI (DE) 2005-03-10 US disclosed
US-6797692-B1 Use of glutamate antagonists for the treatment of cancer IKONOMIDOU HRISSANTHI (DE) 2004-09-28 US disclosed
EP-1427404-A2 TREATMENT OF GLIAL TUMORS WITH GLUTAMATE ANTAGONISTS Nedergaard, Maiken (US) 2004-06-16 EP disclosed
US-20030050224-A1 Blocking glutamate function at an ionotropic glutamate receptor. e.g., N-methyl-D-aspartate receptor, the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid receptor and the kainate receptor; brain disorders; spinal chord NEDERGAARD MAIKEN (US) 2003-03-13 US disclosed
WO-2003015713-A2 TREATMENT OF GLIAL TUMORS WITH GLUTAMATE ANTAGONISTS NEDERGAARD MAIKEN (US) 2003-02-27 WO disclosed
EP-1124553-A1 NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER Ikonomidou, Hrissanthi (DE) 2001-08-22 EP disclosed
EP-1002535-A1 New use of glutamate antagonists for the treatment of cancer Ikonomidou, Hrissanthi (DE) 2000-05-24 EP disclosed
WO-2000024395-A1 NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER IKONOMIDOU HRISSANTHI (DE) 2000-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181454-A1 PHOTOREACTIVE REGULATOR OF GLUTAMATE RECEPTOR FUNCTION AND METHODS OF USE THEREOF GRM2, GRM1, GRM3 DHODH 2356/4885MEN1 4714/4885KMT2A 1832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.